Results 111 to 120 of about 786,314 (373)

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database

Frontiers in Pharmacology
ObjectiveUsing the FDA adverse event reporting system (FAERS) database to analyze the safety profile of Dexmedetomidine and provide guidance for clinical application.MethodsData from the FAERS database from the first quarter of 2004 to the third quarter ...
Yichun Shuai, Zhe Chen, Qiaoqian Wan, Jinzheng Wu, Xin Wang   +4 more
doaj   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Systematic review of the safety of medication use in inpatient, outpatient and primary care settings in the Gulf Cooperation Council countries [PDF]

, 2018
Background Errors in medication use are a patient safety concern globally, with different regions reporting differing error rates, causes of errors and proposed solutions.
Abu Yassin, Abushaiqa, Ackroyd-Stolarz, Al Anany, Al Anazi, Al Hamid, Al Khaja, Al Khaja, Al Khaja, Al Khaja, Al Khaja, Al Odhayani, Al Rahbi, Al Shahaibi, Al-Arifi, Al-Arifi, Al-Dhawailie, Al-Ghamdi, Al-Hussein, Al-Jazairi, Al-Jeraisy, Al-Khani, Al-Olah, Al-Omar, Al-Rashdi, Al-Rowibah, Al-Tajir, Alakhali, Alanazi, Albarrak, Alghamdy, Aljadhey, Aljadhey, Aljadhey, Aljamal, Allan, Almazrou, Alshaikh, Alsulaimi, Altebenaui, American Geriatrics Society Beers Criteria Update Expert Panel, Arabi, Aseeri, ASHP, Bates, Bryony Dean Franklin, Cohen, Dean, Dean, Dean, Dean, Dibbi, Elnour, Ferner, Fick, Flynn, Flynn, Gandhi, Ghaleb, Ghaleb, Hemida, Hepler, Hisham Saad Aljadhey, Hooper, Insley, Irshaid, Jamilah Alsaidan, Jane Portlock, Jha, Jha, Kaushal, Kheir, Khoja, Landis, Lisby, Mahmoud, McLeod, McPhillips, Mendonca, Miller, Mitwally, Morimoto, Morimoto, Nada Atef Shebl, Naranjo, Nebeker, Neville, Rancourt, Rashed, Rashed, Rehmani, Sadat-Ali, Shaughnessy, Sonallah, WHO, World Bank   +95 more
core   +3 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Never events in UK general practice: a survey of the views of general practitioners on their frequency and acceptability as a safety improvement approach [PDF]

, 2019
Background: Never events (NEs) are serious preventable patient safety incidents and are a component of formal quality and safety improvement (Q&SI) policies in the United Kingdom and elsewhere.
Alam, Rahul, Bowie, Paul, Campbell, Stephen, Cheraghi-Sohi, Sudeh, de Wet, Carl, Esmail, Aneez, Stocks, Susan J.   +6 more
core   +2 more sources

Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo

FEBS Open Bio, EarlyView.
The pan‐protein kinase C inhibitor Ro‐31‐8220 demonstrates potent anti‐bladder cancer effects both in vitro and in vivo by suppressing migration/invasion, inducing apoptosis and crucially activating autophagy, where blocking autophagy with chloroquine reduces its cell‐killing efficacy, suggesting its promise as a novel therapeutic candidate requiring ...
Shengjun Fu, Yan Tao, Shan Wu, Yuwen Gong, Youli Zhao, Shaomin Niu, Hui Cheng, You Mu, Na Xu, Ying Wang, Jianzhong Lu, Shanhui Liu, Lanlan Li   +12 more
wiley   +1 more source

Committed to Safety: Ten Case Studies on Reducing Harm to Patients [PDF]

, 2006
Presents case studies of healthcare organizations, clinical teams, and learning collaborations to illustrate successful innovations for improving patient safety nationwide.
David Blumenthal, Douglas McCarthy
core  

Vaccine Adverse Event Reporting System (VAERS) [PDF]

Updated Aug.

core   +3 more sources